Work

Personalized radioiodine therapy for thyroid cancer patients with known disease

Year: 2021

Type: article

Abstract: Radioactive iodine (RAI) 131 I is a targeted therapy for patients with RAI-avid follicular cell-derived thyroid cancer.However, the responsiveness to 131 I therapy varies among thyroid cancer patients mainly owing to differential RAI uptake and RAI radiosensitivity among patients' lesions.A personalized approach to maximize 131 I therapeutic efficacy is proposed based on recent scientific advances and future opportunities.

Source: Faculty Reviews

DOI: 10.12703/r/10-36

Authors: Sissy M Jhiang, Peng Cheng, Fadi A Nabhan, Jennifer A Sipos, Chia-Hsiang Menq

Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University

Language: English

Topic: Thyroid Cancer Diagnosis and Treatment

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funders: Ohio State University, National Institutes of Health, National Cancer Institute